Description: Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Seattle, Washington.
Home Page: kinetabio.com
219 Terry Ave. N
Seattle,
WA
98109
United States
Phone:
206 378 0400
Officers
| Name | Title |
|---|---|
| Mr. Craig W. Philips | President & Secretary |
| Mr. Keith A. Baker | Chief Financial Officer |
| Dr. Thierry Guillaudeux Ph.D. | Chief Scientific Officer |
| Mr. Gary Gentges | Executive Vice President of Corporate Development |
| Ms. Pauline Kenny Esq., J.D. | Advisor |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2016-02-11 |
| Fiscal Year End: | December |
| Full Time Employees: | 11 |